Get the Stockscreener App
3.96
2.46%
-0.10
After Hours:
4.00
0.04
+1.01%
Trevi Therapeutics Inc Stock (TRVI) Latest News
President & CEO GOOD JENNIFER L sale 4,219 shares of Trevi Therapeutics Inc [TRVI] - Knox Daily
A closer look at Trevi Therapeutics Inc (TRVI)’s stock price trends - US Post News
Trevi Therapeutics Inc (TRVI) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
JPMorgan Chase & Co. Buys 69,167 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Down 17.0% in January - MarketBeat
JPMorgan Chase & Co. Has $336,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Certain Common Stock Warrants: of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 31-JAN-2025. - Marketscreener.com
Certain Pre-funded Warrants of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 31-JAN-2025. - Marketscreener.com
Certain Stock Options of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 31-JAN-2025. - Marketscreener.com
Chronic Refractory Cough Pipeline 2024: In-depth Clinical - openPR
Trevi Therapeutics to Participate in Upcoming February Investor Conferences | State News | hjnews.com - The Herald Journal
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Consensus Target Price from Brokerages - Defense World
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $9.31 - MarketBeat
FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs - Defense World
What is Leerink Partnrs' Forecast for TRVI FY2024 Earnings? - MarketBeat
Trevi Therapeutics Announces Abstract Presentation at the Americ - GuruFocus.com
Barclays PLC Acquires 61,317 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Short Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Decreases By 17.0% - MarketBeat
Jane Street Group LLC Sells 33,439 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Trevi Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle
Trevi Therapeutics stock target lifted, holds Buy on treatment progress By Investing.com - Investing.com Canada
What Makes Trevi Therapeutics (TRVI) a New Buy Stock - Yahoo Finance
Trevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Nasdaq
Trevi Therapeutics (TRVI) Stock Price, News & Analysis - MarketBeat
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GuruFocus.com
Geode Capital Management LLC Increases Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Barclays PLC Raises Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics stock soars to 52-week high of $4.68 By Investing.com - Investing.com Australia
Trevi Therapeutics stock soars to 52-week high of $4.68 - Investing.com India
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a - GuruFocus.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
State Street Corp Has $3.18 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75% - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Large Increase in Short Interest - MarketBeat
Trevi Therapeutics Reports Second Quarter 2024 Financial Results - GuruFocus.com
BNP Paribas Financial Markets Purchases 6,764 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Cough in Idiopathic Pulmonary Pipeline Report 2024: Clinical Trials Progress and Therapies by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - The Eastern Progress Online
Trevi Therapeutics sets $50 million stock offering price By Investing.com - Investing.com Australia
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - The Eastern Progress Online
Form 424B5 Trevi Therapeutics, Inc. - StreetInsider.com
Trevi Therapeutics Prices of $50 Million Underwritten Offering - citybiz
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):